2022
DOI: 10.47493/abantmedj.1182158
|View full text |Cite
|
Sign up to set email alerts
|

The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure

Abstract: Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. Development of natriuretic peptide (NP) through inhibition of the neprilysin enzyme is the therapeutic target in HF. Treatment with sacubitril/valsartan has been shown to significantly reduce mortality and hospitalization and rehospitalization rates for HF compared with enalapril. Sacubitril/valsartan may provide significant additional benefit in HF patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 60 publications
0
5
0
Order By: Relevance
“…Also, several mechanisms are considered for ACEI/ARBs, and some BBs, including carvedilol, inhibit erythropoiesis [ 28 30 ]. However, recent studies reported that sacubitril/valsartan (Neprilysin/Angiotensin Receptor Inhibitor) reduces anemia in patients with CRS [ 31 , 32 ]. MRAs may induce erythropoiesis by down-regulating hepcidin.…”
Section: Discussionmentioning
confidence: 99%
“…Also, several mechanisms are considered for ACEI/ARBs, and some BBs, including carvedilol, inhibit erythropoiesis [ 28 30 ]. However, recent studies reported that sacubitril/valsartan (Neprilysin/Angiotensin Receptor Inhibitor) reduces anemia in patients with CRS [ 31 , 32 ]. MRAs may induce erythropoiesis by down-regulating hepcidin.…”
Section: Discussionmentioning
confidence: 99%
“…After ablation of the LBB, mechanical activity in the left ventricle is no longer synchronized, and sustained rapid atrial pacing might lead to left ventricular enlargement and a decrease in left ventricular function. In comparison to other methods used to establish animal models of heart failure, the approach used in this study may be more representative of the pathophysiological mechanisms of heart failure in patients with dilated cardiomyopathy [13,14].…”
Section: Discussionmentioning
confidence: 99%
“…In the PARADIGM-HF trial, the primary outcome of cardiovascular mortality was decreased by 20% in the sacubitril-valsartan arm compared to the enalapril arm [9]. The various beneficial effects of ARNI in cardiac re-modelling, cardiac function, metabolic effects and decreased SCD have been well documented [10]. Thus, ARNI treatment has an important role in the therapy for HF [11].…”
Section: Introductionmentioning
confidence: 99%